pharma

Eli Lilly Dominates High-Growth Healthcare Market

Eli Lilly maintains its position as a leader in a key high-growth healthcare market, though its elevated valuation leaves little room for error and creates increased risk for investors. The pharmaceutical company's strong performance reflects demand for innovative treatments in expanding therapeutic categories. However, the stock's premium valuation means any growth disappointment could trigger significant selloffs.